Free vaccine will be provided to prioritized beneficiaries including one crore healthcare and two crore frontline workers in the first phase
The Drug Controller General of India (DCGI) has approved two COVID-19 vaccines in India for emergency use: Oxford-AstraZeneca's coronavirus vaccine Covishield (manufactured by Serum Institute of India) and Covaxin developed by Bharat Biotech.
On Jan 2, 2021, a nation-wide vaccination dry run was conducted in 125 districts across 285 sites. “The objective of the drive is to gear up for the rollout of COVID-19 vaccine across the country. The run will also assess operational feasibility in the use of Co-WIN application in the field environment, to test the linkages between planning and implementation and to identify the challenges and guide the way forward prior to actual implementation. This is also expected to give confidence to programme managers at various levels,” he said.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.